List view / Grid view
Strike NGS workflow gold with our broad portfolio of automation solutions, delivering reliable, high-throughput results. But don't take our word for it! Hear from our customer.
Check out our library of NGS-related webinars from global researchers and industry professionals to explore possibilities with our Biomek automated workstations and Echo acoustic liquid handlers.
Generate accurate data by automating your NGS workflows with Beckman Coulter Life Sciences’ flexible automated liquid handling solutions that deliver reliable results.
Explore how to apply our acoustic and tip-based liquid handling solutions for your NGS workflows in metagenomics, sample QC, RNASeq, microbiome, SARS-CoV 2 to name a few.
Automation solutions from Beckman Coulter Life Sciences alleviate your library prep pain points, whether you need automation for a few samples or a high-throughput solution.
Work with one trusted partner for instruments, software, consumables and service to help keep your laboratory running smoothly. Smooth processes save time, money and maximise your lab’s ROI.
30 June 2022 | By Brooks Automation
Watch this on-demand webinar to learn how collaborative robots are improving accuracy and efficiency in today’s laboratories.
Dr Erik Vernet, Director of Antibody Technology at Novo Nordisk, discusses antibody discovery and development workflows, including the role of informatics processes, in this Q&A.
Dr Richard Goodwin, Head of Imaging & AI, Clinical Pharmacology & Safety Sciences at AstraZeneca, explores the latest innovation in early therapeutic development – spatial biology.
Using a machine learning model, scientists could predict not only the virus an antibody will attack, but which features on the pathogen the antibody binds to.
The COVID-19 pandemic has placed a spotlight on the discovery and development of biotherapeutics, for both the treatment and prevention of diseases. In this article, industry experts discuss the emerging trends they see in biotherapeutic development and how they predict the field will evolve in the near future.
Read this bulletin to learn about a Bio-Rad study where they developed and tested a 16-parameter flow cytometry panel applicable to the interrogation of a range of biologically relevant markers of T cell activation.
Scientists have created a pipeline for identifying, prioritising and evaluating potential tumour antigens for personalised cancer vaccines.
In this exclusive piece, Adrien Châtillon, Co-Founder and CEO of Actipulse Neuroscience, explores the future of treatment for diseases that impact mental health.
Sanofi and Exscientia will develop up to 15 novel drug candidates by leveraging the latter's AI discovery and optimisation platform.
